14 June 2024

Physiomics plc

("Physiomics" or the "Company")

Physiomics Adds Modeling and Data Science Functionality to DoseMe's Precision Dosing Platform

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has re-engaged with DoseMe and agreed to implement the Company's personalised dosing software on the DoseMeRx platform as well as explore research collaborations. The Physiomics software will be made available to selected DoseMe clients, initially on a research basis, but with the objective of adding paid functionality later, in particular relating to the potential for the software to be able to provide decision support around the use of granulocyte colony stimulating factor ("GCSF").

Background

The Company's personalised dosing software has been developed primarily with grant funding from UK bodies including £68,000 from Innovate UK (March 2018), £150,000 from the National Institute for Health and Care Research to fund the PARTNER study (March 2020) and most recently £137,376 from Innovate UK and The Office for Life Sciences to fund the PREDICT-ONC study (November 2023).

The software was initially focused on cancer chemotherapies (such as docetaxel) that can cause reduced white cell counts (neutropenia) and potentially lead to infection and hospitalisation. Based on a series of blood tests in the early weeks of a patient's chemotherapy treatment, the software is calibrated for each individual to provide an estimate of the extent and timing of neutropenia. It also allows clinicians to amend the dose of chemotherapy and see the predicted effect on neutrophil levels.

Collaboration with DoseMe

The Company first entered into a collaboration with DoseMe at the end of 2020 and the two companies worked together during 2021 to implement a demonstration version of the Physiomics software to facilitate review with US based pharmacists and clinicians. Feedback from this exercise suggested that the need for additional blood tests to calibrate the software could be a disincentive to its use and that, in addition, some focus on more modern, costly drugs would be of interest. During 2022 DoseMe's then parent company announced its planned divestment and DoseMe was acquired by a private equity group in early 2023. During that year, in parallel with applying for and winning a further Innovate UK grant, the Company re-engaged with DoseMe's new management, culminating in today's announcement of the plan to launch the Company's dosing software on the recently upgraded and expanded DoseMeRx platform and to make it available, initially on a research basis, to selected US clients. It is expected that the software will be made available in the second half of 2024. The two companies have also agreed to identify one or more centres in the US, currently served by DoseMe, that have historical patient data that could be used to further develop Physiomics' dosing software and specifically to enhance its ability to support decision making around the use of the expensive biological drug GCSF which is commonly used by clinicians to counteract the neutropenic tendency of chemotherapeutic agents.

Moving Forwards

The focus of the Company's personalised dosing initiatives going forwards will be to expand the capability of the software to support dosing decision making around not only chemotherapeutic agents but GCSF. Both the ongoing PREDICT-ONC study and potential secondary research with DoseMe clients in the US will support this objective. In parallel, the Company is seeking ways to make the blood sampling required by its software more convenient for patients. This can potentially be achieved by using the software in other settings where frequent blood sampling already occurs, but also through exploration of the use of new diagnostic devices that can obtain and analyse blood samples in community or home settings (such at that being developed by our partner company Beyond Blood Diagnostics).

As the Company continues to develop its personalised dosing software, it will actively consider the most appropriate way to ring fence resources for this part of its business. Options under consideration include creation of a dedicated business unit, creation of a wholly owned subsidiary or a joint venture with a party with complementary technology/ capabilities. As further progress is made towards one of these, further updates will be provided accordingly.

Dr Peter Sargent, CEO, commented: *"I'm really pleased that we've able to progress this initiative and the team are excited to build upon the partnership with DoseMe to further develop our Personalised Oncology Dosing Software".*

Paul Edwards, CEO, DoseMe, commented: *"Oncology is one area that will benefit tremendously from precision dosing. The results from the initial research point to constructive data output that will enhance dosing decision and ultimately, make life changing differences for patients."*

Enquiries:

Physiomics plc
Dr Peter Sargent, CEO
+44 (0)1235 841575

Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494

DoseMe
Alison Guzzio
+1 484 459 3243

Notes to Editor

About Physiomics

Physiomics plc combines cutting edge PKPD and QSP modelling and data science techniques, along with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys.
Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design research across discovery, pre-clinical and clinical studies.
Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

About DoseMe

DoseMe combines smart technology with science, leveraging clinically-validated PK/PD models, patient characteristics, drug concentrations, and genotype to accurately individualize a dose in seconds. The platform is HIPAA, ISO & FDA compliant and the only Bayesian dosing platform to be HITRUST CSF certified. For more information on successful applications of its products, DoseMeRx and DoseMe Analytics, visit https://doseme-rx.com/success-stories

END

NRAFIFSRRSISLIS